Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System LymphomaWada-Shimosato, Yuko MD*; Ikeda, Junji MD*; Tsujimoto, Shin-ichi MD*; Sasaki, Koji MD*; Yanagimachi, Masakatsu MD, PhD*; Kajiwara, Ryosuke MD, PhD*; Shiba, Norio MD, PhD*; Murata, Hidetoshi MD, PhD†; Kawahara, Nobutaka MD, PhD†,✠; Yamanaka, Shoji MD, PhD‡; Tanoshima, Reo MD, PhD*; Ito, Shuichi MD, PhD*Journal of Pediatric Hematology/Oncology: August 17, 2018 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/MPH.0000000000001291 Clinical and Laboratory Observations: PDF Only Buy PAP Abstract Author InformationAuthors Article MetricsMetrics Primary central nervous system lymphoma (PCNSL) is a rare and aggressive type of extranodal non-Hodgkin lymphoma that carries an unsatisfactory prognosis. Treating refractory PCNSL is challenging because of resistance to conventional cytotoxic and intrathecal chemotherapies. Therefore, novel therapeutic approaches are needed. Here, we report a 12-year-old boy with CD20-positive PCNSL, which was refractory to combination chemotherapy and intravenous rituximab. However, the patient achieved complete remission after repeated intraventricular rituximab administration. The results of this case indicate that intraventricular rituximab is an effective option to treat refractory PCNSL in children. Departments of *Pediatrics †Neurosurgery ‡Pathology, Yokohama City University School of Medicine, Yokohama, Japan ✠ Deceased. The authors declare no conflict of interest. Reprints: Shin-ichi Tsujimoto, MD, Department of Pediatrics, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan (e-mail: firstname.lastname@example.org). Received March 8, 2018 Accepted July 7, 2018 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.